Complement Activation and the Production of Inflammatory Mediators During the Treatment of Severe Sepsis in Humans

References

• Mahoney J R, Beutler B A, Le Trang N, Vine W, Ikeda Y, Kawakami M, Cerami A. Lipopolysaccharide-treated raw 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-li cells. J Immunol 1985; 134: 1673–1675
   PubMed Web of Science ®Google Scholar
• Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced raw 264.7 cells. J Exp Med 1985; 161: 984–995
   PubMed Web of Science ®Google Scholar
• Beutler B, Greenwald D, Hulmes J D, Chang M, Pan Y, Mathison J, Ulevitch R. Identify of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 552–554
   PubMed Web of Science ®Google Scholar
• Vellenga E, Rambaldi A, Ernst T J, Ostapovicz D, Griffin J D. Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood 1988; 71: 1529–1532
   PubMed Web of Science ®Google Scholar
• Dinarello C A. The biology of interleukin 1 and comparison to tumor necrosis factor. Immunol Lett 1987; 16: 227–232
   PubMed Web of Science ®Google Scholar
• Le J, Vilcek J. Interleukin 6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588–602
   PubMed Web of Science ®Google Scholar
• Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584–587
   PubMed Web of Science ®Google Scholar
• Malik S, Balkwill F R. Tumour necrosis factor. Br Med J 1989; 280–280
   Google Scholar
• Beutler B. The molecular basis of shock: the role of cachectin. Update in intensive care and emergency medicine, no. 8, J L Vincent. Springer-Verlag, Berlin-Heidelberg-New York 1989; 53–57
   Google Scholar
• Beutler B. Cachectin in tissue injury, shock, and related states. Crit Care Clin 1989; 5: 353–367
   PubMed Web of Science ®Google Scholar
• Tracey K J, Cerami A. Cachectin/tumor necrosis factor and other cytokines in infectious disease. Curr Opin Immunol 1989; 1: 454–461
   PubMed Web of Science ®Google Scholar
• Tracy K J, Vlassara H, Cerami A. Cachectin/tumor necrosis factor. Lancet 1989; 1: 1122–1126
   PubMed Web of Science ®Google Scholar
• Cannon J G, Tompkins R G, Gelfland J A, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161: 79–84
   PubMed Web of Science ®Google Scholar
• Beutler B. Orchestration of septic shock by cytokines: the role of cachectin (tumor necrosis factor). Molecular and cellular mechanisms of septic shock. Alan R. Liss, New York 1989; 219–235
   Google Scholar
• Fearon D T, Ruddy S, Schur P H, McCabe W R. Activation of the properdin pathway of complement in patients with gram-negative bacteremia. N Engl J Med 1975; 292: 937–951
   PubMed Web of Science ®Google Scholar
• Robinson J A, Klodnycky M L, Loeb H S, Racic M R, Gunnar R M. Endotoxin, prekailikrein, complement and systemic vascular resistance. Am J Med 1975; 59: 61–67
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Mollnes T E, Kierulf P. Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 1989; 160: 58–65
   PubMedGoogle Scholar
• Hack C E, Nuijens J H, Strack van Schijndel R JM, Abbink J J, Eerenberg A JM, Thijs L G. A model for the interplay of inflammatory mediators in sepsis – a study in 48 patients. Int Care Med 1990; 16: S187–S191
   Web of Science ®Google Scholar
• Lundberg C, Marceau F, Hugli T E. C5a-induced hemodynamic and hematological changes in the rabbit. Am J Pathol 1987; 128: 471–483
   PubMed Web of Science ®Google Scholar
• Hammerschmidt D E, Hudson L D, Weaver L J, Craddock P R, Jacob H S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Lancet 1980; 1: 947–949
   PubMed Web of Science ®Google Scholar
• Okusawa S, Yancey K B, van der Meer J WM, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. J Exp Med 1988; 168: 443–448
   PubMed Web of Science ®Google Scholar
• Scholz W, McClurg M R, Cardenas G J, Smith M, Noonan D J, Hugli T E. C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 1990; 57: 297–307
   PubMedGoogle Scholar
• Dofferhoff A SM, Bom V JJ, Vries-Hospers de H G, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor (PAI) and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med. 1992; 20: 185–192
   PubMed Web of Science ®Google Scholar
• Knaus W A, Draper E A, Wagner D P, Zimmerman J E. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818–829
   PubMed Web of Science ®Google Scholar
• Kern P, Hemmer C J, Van Damme J, Gruss H J, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989; 87: 139–143
   PubMed Web of Science ®Google Scholar
• Helle M, Boeije L, Aarden L A. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 1988; 18: 1535–1540
   PubMed Web of Science ®Google Scholar
• Hack C E, Groot de E R, Felt-Boersma R JF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704–1710
   PubMed Web of Science ®Google Scholar
• Garner R, Chater B V, Brown D L. The role of complement in endotoxin shock and disseminated intravascular coagulation: experimental observations in the dog. Br J Haematol 1974; 28: 393–401
   PubMed Web of Science ®Google Scholar
• Hsueh W, Sun X, Rioja L N, Gonzalez-Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 1990; 70: 309–314
   PubMed Web of Science ®Google Scholar
• Cavaillon J M, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20: 253–257
   PubMed Web of Science ®Google Scholar
• Hack C E, Nuijens J H, Felt-Bersma R JF, et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86: 20–26
   PubMed Web of Science ®Google Scholar
• Osterud B. Interaction of endotoxins, blood elements and the vessel wall. Bacterial endotoxins: structure, biomedical significance, and detection with the limulus amebocyte lysate test. Alan R Liss, New York 1985; 67–78
   Google Scholar
• Hack C E, Thijs L G. The orchestra of mediators in the pathogenesis of septic shock: a review, Submitted
   Google Scholar
• Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740–745
   PubMed Web of Science ®Google Scholar
• Gamble J R, Harlan J M, Klebanoff S J, Vadas M A. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 1985; 82: 8667–8671
   PubMed Web of Science ®Google Scholar
• Smedley L A, Tonnesen M G, Sandhaus R A. Neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 77: 1233–1243
   PubMed Web of Science ®Google Scholar
• Kane M A, May J E, Frank M M. Interactions of the classical and alternate complement pathway with endotoxin lipopolysaccharide. J Clin Invest 1973; 52: 370–375
   PubMed Web of Science ®Google Scholar
• DiScipio R G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 1982; 45: 587–595
   PubMed Web of Science ®Google Scholar
• Morrison D C, Kline L F. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS). J Immunol 1977; 118: 362–368
   PubMed Web of Science ®Google Scholar